IDRx, Inc is hoping to use its latest round of venture capital funding to advance its drug IDRX-42 to tackle a sarcoma subtype, gastrointestinal stromal tumor (GIST), that remains underserved despite targeted therapies being available for many years.
IDRx Looks To Challenge Standard-Of-Care Sunitinib In Second-Line GIST
The company raised $120m in a series B funding round and plans to start a Phase III study of IDRX-42 next year. Scrip talked to IDRx’s execs about the company’s development strategy.
